| Literature DB >> 32952484 |
Pamela Nair Silva-Holguín1, Simón Yobanny Reyes-López1.
Abstract
Innovative and improved antimicrobial agents by nanotechnology are developed to control and mitigation of resistant microorganisms. Nanoparticles of metals or oxide metals be able to be toxic to bacteria, demonstrating biocidal behaviors at low concentrations. The integration of silver nanoparticles in ceramic matrices has enhanced the antimicrobial performance, resulting in the search for new composites with improved bactericidal properties. The aim of this study was to prepare and characterize hydroxyapatite-silver nanocomposite and evaluate its antimicrobial properties against various Gram-positive and negative bacteria related to drug-resistance infections. Hydroxyapatite nanopowders were produced by sol-gel and silver nanoparticles were synthesized by reduction of Ag+ions with the simple addition of gallic acid. Hydroxyapatite-silver composite (HAp-AgNPs) was prepared by adsorption of AgNPs at several concentrations. The results of UV-visible spectroscopy, dynamic light scattering, and transmission scanning electron microscopy revealed the existence of AgNPs with diameters around 6 nm. Scanning electron microscopy and energy dispersive X-ray spectroscopy corroborated the presence of silver disseminated over the surface of hydroxyapatite nanopowders. All HAp-AgNPs composites demonstrated excellent antibacterial effect even at lower silver concentration. HAp-AgNPs composites have a higher possibility for medical applications focused no the control of microorganisms with drug-resistance.Entities:
Keywords: antibacterial activity; drug-resistance; hydroxyapatite; nanocomposites; silver nanoparticles
Year: 2020 PMID: 32952484 PMCID: PMC7485164 DOI: 10.1177/1559325820951342
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
Figure 1.Synthesized hydroxyapatite, UV-Vis spectrum (A), infrared spectrum (B), Raman spectrum (C), EDX analysis (D), STEM micrographs backscattered (E) and secondary electrons (F).
Figure 2.Transmission electron microscope micrograph of AgNPs (A) and their UV-vis spectra (B).
Figure 3.UV-vis spectrum (A), UV-vis spectrum magnification (B), FT-IR spectrum (C), Raman spectrum (D), X-ray diffractogram (E), HAp- AgNPs image, from left to right, HAp, HAp- AgNPs at 0.5, 1, 2.5 and 5 mM (F).
Figure 4.STEM micrographs of HAp-AgNPs powder at: 0.5 mM (A), 1 mM (D), 2.5 mM (G) and 5 mM (J). MEB-SE micrographs of HA- AgNPs powder at: 0.5 mM (B), 1 mM (E), 2.5 mM (H) and 5 mM (K). EDX analysis of 0.5 mM (C), 1 mM (F), 2.5 mM (I) and 5 mM (L).
Figure 5.Compositional analysis EDX_SEM of 5 mM HAp-AgNPs: A) micrograph on secondary electrons, B) silver, C) phosphorus, D), calcium, E) oxygen and F) carbon.
Figure 6.Particle size versus zeta potential.
Figure 7.Inhibition halos for: A) Escherichia coli, B) Klebsiella oxytoca, C) Pseudomonas aeruginosa, D) Staphylococcus aureus, E) Streptococcus mutans and F) Bacillus subtilis.
Figure 8.Box Plot of the inhibition halo of HAp-AgNPs powders.
Figure 9.Percent inhibition of HAp-AgNPs powders.
Figure 10.Box Plot of the inhibition of HAp-AgNps powders.
Literature Review of Research on the Bactericidal Effect of Silver and Silver Nps.
| Referencia | Material | Inoculum | Particle size (nm) | Concentration AgNPs | Bacterium/(MIC) |
|---|---|---|---|---|---|
| Present work | HA-AgNPs | 1.3 × 106 CFU/mL | 5.6 ± 2.9 | 0.5 mM (0.027mg/g), |
|
| Kim et al. | Silver nanoparticles | 107 CFU/ mL | 13.4 ± 2.6 | 0.2 – 33 nM |
|
| Raffi et al., | Silver nanoparticles | 104 CFU/mL | 16 | 0, 20, 40, 60, 80 and 100 µg/mL |
|
| Nirmala, R., et al., Journal of Nanoparticle Research,
(2010) 13(5), 1917–1927.[ | Bovine femur bone hydroxyapatite-silver nanoparticles | 1.5 × 106-8 UFC/mL | 8–20 | 0, 1, 3, and 5% | E. coli / 3% |
| Mocanu, A, et al., Applied Surface Science, (2014) 298, 225–235.[ | Nano hydroxyapatite doped with silver | 106 UFC/ml | 12.0 ± 5.0 | 2, 2.5, 3, 3.6, 4.5 and 5.4% |
|
| Pazos-Ortiz, E., et al., Journal of Nanomaterials,
Volume 2017, 7 pages, ID 485121.[ | PCL-AgNPs | 1.3 × 106 CFU/mL | 5.6 ± 2.9 | 12.5 mM (0.012 mg/g), |
|
| Riaz et al., | Silver doped hydroxyapatite | 105 CFU/mL | - | 0, 0.1, 0.3, 0.5, 0.7 M of AgNO3 |
|
| Biao, L. et al., | Proanthocyanidins-functionalized Ag nanoparticles | 108 CFU/mL | 33.2 ± 5.6 | 0.49 to 62.8 μg/mL |
|
| Zhou, Q. et al. Colloids and Surfaces A: Physicochemical
and Engineering Aspects, (2020) 585, 124081.[ | HApNPs | 105 CFU/mL | - | 0.01 M, 0.05 M, and 0.1 M of AgNO3 |
|
| Menazea, A. A., et al., Applied Surface Science, (2020) 145299.[ | AgNPs@Se-CHAP/PCL composite fibers | 1.5 × 108 CFU/mL | 80 - 140 | Depositions at time of 5, 10, 15, and 20 min. |
|